Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients
暂无分享,去创建一个
Jun Wang | Li Zhang | Wei Zhong | Jing Zhao | Fan Yang | J. Zhao | Li Zhang | Jun Wang | Fan Yang | W. Zhong | Mengzhao Wang | Xiao Zhao | Ru-Bing Han | Long-Yun Li | Meng-Zhao Wang | Long-yun Li | Xiao Zhao | Rubing Han
[1] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[2] A. Gemma,et al. F1000 highlights , 2010 .
[3] L. Paz-Ares,et al. PD2-3-3: High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS) , 2007 .
[4] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[5] Young Tae Kim,et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] K. Nishio,et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) , 2007, British Journal of Cancer.
[7] 木村 英晴. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer , 2006 .
[8] K. Nishio,et al. EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[10] P. Jänne,et al. Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.
[11] D. Tenen,et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. , 2007, Lung cancer.
[12] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[13] K. Nishio,et al. Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer , 2006, Clinical Cancer Research.
[14] R. Rosell,et al. Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] M. Ladanyi,et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. , 2011, Lung cancer.
[16] N. Zhong,et al. Detection of epidermal growth factor receptor mutations in plasma by mutant‐enriched PCR assay for prediction of the response to gefitinib in patients with non‐small‐cell lung cancer , 2009, International journal of cancer.
[17] F. O. Fackelmayer,et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.
[18] S. Toyooka,et al. Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay , 2006, Clinical Cancer Research.
[19] M. Paci,et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. , 2009, Lung cancer.
[20] L. Sobin,et al. TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.
[21] J. Tong. Quantification of Circulating Cell-Free DNA in the Serum of Patients with Obstructive Sleep Apnea-Hypopnea Syndrome , 2010 .
[22] R. Rosell,et al. High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS) , 2007 .
[23] L. Mao,et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Li-jian Zhang,et al. Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients , 2010 .
[25] H. Wan,et al. Quantification of Circulating Cell-Free DNA in the Serum of Patients with Obstructive Sleep Apnea–Hypopnea Syndrome , 2010, Lung.
[26] P. Krawczyk,et al. The Applicability of a Predictive Index for Second- and Third-Line Treatment of Unselected Non-Small-Cell Lung Cancer Patients , 2011, Respiration.
[27] T. Mok,et al. Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients , 2009, Clinical Cancer Research.
[28] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[29] Koichi Goto,et al. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.